DENVER, CO--(Marketwired - Dec 6, 2016) - American Cannabis Company, Inc. (OTCQB: AMMJ) (the "Company"), a full-service business-to-business consulting solutions provider, and seller of ancillary products to the cannabis industry, today announced it has signed another client in Pennsylvania who will be applying for a dispensary license in the state's upcoming medical marijuana program. ACC expects to leverage this contract to secure additional revenues through long-term consulting agreements and potential sales of ancillary products.
Corey Hollister, CEO of American Cannabis Company, commented: "We are excited to be working with this client in the pursuit of a state licensed dispensary operation within the upcoming Pennsylvania medical marijuana program. As more states adopt medical marijuana programs, we are seeing a variety of market structures for license ownership ranging from vertically integrated frameworks all the way to decoupled and hybrid models. Pennsylvania has selected a hybrid model that permits for standalone dispensary operations, and our client is well positioned to capitalize on this opportunity."
About American Cannabis Company, Inc.:
American Cannabis Company, Inc. offers end-to-end solutions to existing and aspiring participants in the cannabis industry. We utilize our industry expertise to provide business planning and market assessment services, assist state licensing procurement, create business infrastructure and implement operational best practices. American Cannabis Company also developed and owns a portfolio of branded products including: The patented Satchel™, SoHum Living Soils™, The Cultivation Cube™ and The High Density Cultivation System™. In addition, we design and provide other industry specific custom product solutions. The building and development of our brands and product suite is based on our Geoponics Philosophy, "the art and science of agriculture in soil."
For more information, please visit:
Forward Looking Statements
This news release contains "forward-looking statements" which are not purely historical and may include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs and results of new business opportunities and words such as "anticipate", "seek", intend", "believe", "estimate", "expect", "project", "plan", or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects, the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-K for the most recent fiscal year, our quarterly reports on Form 10-Q and other periodic reports filed from time-to-time with the Securities and Exchange Commission. For more information, please visit www.sec.gov.